Skip to content
Prof. Dr. Mustafa Özdoğan · Medical Oncologist

A 6-Week Dosing Schedule for the Cancer Immunotherapy Pembrolizumab (Keytruda) Receives FDA Approval

A 6-Week Dosing Schedule for the Cancer Immunotherapy Pembrolizumab (Keytruda) Receives FDA Approval

On 28 April 2020, the US Food and Drug Administration (FDA) granted accelerated approval for a new regimen of 400 mg every 6 weeks for the immunotherapy drug pembrolizumab (Keytruda), for all cancers for which it had been approved up to that point.

This approval may help reduce how often cancer patients need to visit the hospital while the COVID-19 Pandemic is ongoing.

The approval was based on pharmacokinetic modeling comparing pembrolizumab 400 mg every 6 weeks with the following three different doses: 2 mg/kg every 3 weeks, 200 mg every 3 weeks, and 10 mg/kg every 2 weeks. The pharmacokinetic modeling was supported by the KEYNOTE-555 clinical trial through interim analyses of pharmacokinetics and overall response rate in an enrolled patient group (Cohort B). Cohort B of KEYNOTE-555 was an international, single-arm, multicenter study of patients with advanced melanoma who had not previously received immunotherapy, enrolling 101 patients.

This new dosing regimen was approved under accelerated approval based on pharmacokinetic, exposure–efficacy, and exposure–safety data. Continued approval for this indication may depend on verification and description of clinical benefit in a confirmatory trial.

This application was approved more than five months before the FDA target date.

For which cancers does Keytruda (Pembrolizumab) have FDA approval?

Sources

FDA approves new dosing regimen for pembrolizumab.
fda.gov - 28 April 2020

Appointment request

DROZDOGAN AI

Explore this article together

Ask about the article and read answers alongside published sources from our site.

DROZDOGAN AI

Drozdogan Assistant

A 6-Week Dosing Schedule for the Cancer Immunotherapy Pembrolizumab (Keytruda) Receives FDA Approval

Ask about the article and read answers alongside published sources from our site.

Conversation and privacy information

Drozdogan Assistant answers this conversation. Authorized site administrators may review it for quality. Do not share personal information.

Replies use OpenAI infrastructure. Questions and replies are processed by that service; conversation records are stored on our site. Do not share identifying, contact or personal health information.

0 / 1000

For information only; no personal diagnosis or treatment advice.

Related articles

Explore other articles on this topic.

Stay informed

Receive new articles and scientific updates by email.

Google Analytics runs on public pages independently of this window and may use analytics cookies. Your choice here controls external services only.

Cookie policy